TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

Tempest Announces Strategic Acquisition of New Dual-CAR T Programs from Factor with Simultaneous Runway Extension Projected to Mid 2027

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Tempest Therapeutics
Tempest Announces Strategic Acquisition of New Dual-CAR T Programs from Factor with Simultaneous Runway Extension Projected to Mid 2027

Tempest Therapeutics plans to acquire dual-CAR T programs from Factor Bioscience in an all-stock transaction, expanding its clinical-stage pipeline and extending its operational runway to mid-2027. The acquisition includes a clinical-stage CD19/BCMA dual-CAR T program and is expected to close in early 2026.

Insights
HAS   positive

New partnership with Netflix to create merchandise for popular content


TPST   positive

Company is diversifying pipeline, extending financial runway, and acquiring promising clinical-stage programs with potential value-creating milestones